Date | Title | Description | |
---|---|---|---|
12 Apr 2021 | On business and financial situation | The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. | Download |
02 Mar 2021 | On business and financial situation | The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
02 Mar 2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
Pages
Date | Title | Description | |
---|---|---|---|
31 May 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 24 May and 30 May 2024 | Download |
24 May 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 17 May and 23 May 2024 | Download |
21 May 2024 | Announcement of general shareholders’ meeting | Publication of the announcement of the call to the General Shareholders’ Meeting and the documentation related thereto. | Download |
17 May 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 10 May and 16 May 2024 | Download |
10 May 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 2 May and 9 May 2024 | Download |
Pages
Date | Title | Description | |
---|---|---|---|
07 Nov 2019 | Information on P&L | ROVI releases the first nine months 2019 results presentation | Download |
03 Oct 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the third quarter of 2019 | Download |
05 Sep 2019 | Others on business performance and financial information | The Company informs about the construction of a second heparin plant in Granada | Download |
30 Jul 2019 | Information on P&L | ROVI releases the first half 2019 results presentation | Download |
30 Jul 2019 | Information on P&L | ROVI releases the press release related to the first half 2019 financial results | Download |